Psoriatic Arthritis (PsA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Psoriatic Arthritis (PsA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in PsA therapeutics.
  • There will be more than 6 million prevalent cases of PsA in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast.
  • There are 14 leading marketed drugs for the treatment of PsA, Janssen is the key player in the PsA landscape with five marketed products.
  • R&D activity in PsA is robust globally, with three products in the pre-registration phase in the US, Japan, and EU, and 14 products in Phase III development across the global markets.
  • Commercial sponsors dominate clinical trial development in PsA, with the US emerging as the key country for conducting Phase III trials in PsA.
  • During the past 12 months, three mergers and acquisitions, and five strategic alliances deal involving companies developing PsA assets have been completed.
Scope

GlobalData’s PsA: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the PsA market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsA market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Key Findings
  • Disease Overview
    • Disease Etiology
  • Epidemiology Overview
    • Epidemiology Overview - Total Prevalent Cases of PsA in 2023
  • Treatment Overview
    • Treatment Guidelines
    • Treatment Algorithm
  • Marketed Drugs Assessment
    • Marketed Drugs - Leading Marketed Drugs in PsA
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Route of Administration
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drug Profile: AbbVie’s Humira
    • Marketed Drug Profile: Janssen’s Stelara
    • Marketed Drug Profile: Amgen’s Enbrel
    • Marketed Drug Profile: Novartis’s Cosentyx
    • Marketed Drug Profile: Janssen’s Remicade
    • Marketed Drug Profile: Janssen’s Simponi
    • Marketed Drug Profile: AbbVie’s Skyrizi
    • Marketed Drug Profile: Pfizer’s Xeljanz
    • Marketed Drug Profile: UCB’s Cimzia
    • Marketed Drug Profile: Eli Lilly’s Taltz
    • Marketed Drug Profile: Janssen’s Tremfya
    • Marketed Drug Profile: AbbVie’s Rinvoq
  • Pricing and Reimbursement Assessment
    • Marketed Drugs - Annual Cost of Therapy for Intravenous Formulations in PsA
    • Marketed Drugs - Annual Cost of Therapy for Oral Formulations in PsA
    • Marketed Drugs - Annual Cost of Therapy
    • Marketed Drugs - Time to Pricing and Reimbursement for Adalimumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Abatacept
    • Marketed Drugs - Time to Pricing and Reimbursement for Certolizumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Etanercept
    • Marketed Drugs - Time to Pricing and Reimbursement for Golimumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Guselkumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Infliximab
    • Marketed Drugs - Time to Pricing and Reimbursement for Ixekizumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Risankizumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Secukinumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Ustekinumab
    • Marketed Drugs - Time to Pricing and Reimbursement for Apremilast
    • Marketed Drugs - Time to Pricing and Reimbursement for Tofacitinib
    • Marketed Drugs - Time to Pricing and Reimbursement for Upadacitinib
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview - Pre-registration and Phase III Pipeline Drugs in PsA
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in PsA
    • Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Musculoskeletal Disorders and in PsA
  • Clinical Trials Assessment
    • Clinical Trials in PsA - Historical Overview
    • Clinical Trials in PsA - Overview by Phase
    • Clinical Trials in PsA - Overview by Status
    • Clinical Trials in PsA - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in PsA - Trials with a Virtual Component
    • Clinical Trials in PsA - Geographic Overview
    • Clinical Trials in PsA - Single-Country and Multinational Trials by Region
    • Clinical Trials in PsA - Top Sponsors with Breakdown by Phase
    • Clinical Trials in PsA - Top Sponsors with Breakdown by Status
    • Clinical Trials in PsA - Overview by Endpoint Status
    • Clinical Trials in PsA - Overview by Race and Ethnicity
    • Clinical Trials in PsA - Enrollment Data
    • Clinical Trials in PsA - Overview of Sites by Geography
    • Clinical Trials in PsA - Top 20 Countries for Trial Sites
    • Clinical Trials in PsA - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for PsA
  • Deals Landscape
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in PsA by Region
    • Deals Landscape - Recent Mergers and Acquisitions, and Strategic Alliances in PsA
  • Commercial Assessment
    • Commercial Assessment - Key Market Players in PsA
  • Future Market Catalysts
    • Future Market Catalysts - Upcoming Market Catalysts in PsA
  • Appendix
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings